13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

Are immunotherapies still an investment eldorado?

Are immunotherapies still an investment eldorado?

Investment in immunotherapy in 2018 is still attractive and sought out; what is its growth
potential after several years of being an investment blockbuster? What have been the 2018
investment successes in immunotherapy? Will immunotherapy disrupt the oncology market?
Are we at the growth, maturity, or saturation stage when we talk about investing in
immunotherapy?

Chris Shelley

Partner
United Kingdom
Penningtons Manches LLP

Khatereh Ahmadi

Head of Search and Evaluation, European BD&L team
United Kingdom
MSD

Madiha Derouazi

Founder and CEO
Switzerland
AMAL Therapeutics

Bram Vanparys

Partner – Health & Care
Belgium
Gimv

Juan García

CEO
Spain
BioSeed Capital
Scroll to Top
  • No products in the cart.